New combinations and targets in advanced prostate cancer
In yesterday’s post on novel targets in advanced prostate cancer, we looked at a potential new concept that is emerging and being evaluated in clinical trials.
Today, we continue that approach with a look at another novel – and quite different target – as well as ways of repurposing old drugs to help potentially overcome the drug resistance seen with newer therapies for this disease.
Warning: the concepts discussed here may well take you by surprise, although they are based on rational and logical evidence from recent scientific research.
To learn more, subscribers can simply log in.
This content is restricted to subscribers
